Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10360703" target="_blank" >RIV/00216208:11110/17:10360703 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/17:10360703

Result on the web

<a href="http://dx.doi.org/10.1016/j.autrev.2017.04.010" target="_blank" >http://dx.doi.org/10.1016/j.autrev.2017.04.010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.autrev.2017.04.010" target="_blank" >10.1016/j.autrev.2017.04.010</a>

Result language

angličtina

Original language name

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Original language description

Background: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with improved long-term outcomes. One can therefore speculate that early initiation of highly effective immunotherapies, with an average efficacy that is superior to the typical first-line therapies, could further improve relapse and disability outcomes. However, the most common treatment strategy is to commence firstline therapies, followed by treatment escalation in patients who continue to experience on-treatment disease activity. While this monitoring approach is logical, the current lack of effective regenerative or remyelinating therapies behoves us to consider high-efficacy treatment strategies from disease onset (including induction therapy) in order to prevent irreversible disability. Objective: In this systematic review, we evaluate the effect of high-efficacy immunotherapies at different stages of MS. Methods: A systematic review of literature reporting outcomes of treatment with fingolimod, natalizumab or alemtuzumab at different stages of MS was carried out. Results and conclusions: Twelve publications reporting relevant information were included in the systematic review. The literature suggests that treatment with high-efficacy immunotherapies is more potent in suppressing relapse activity when initiated early vs. with a delay after the MS diagnosis. The evidence reported for disability and MRI outcomes is inconclusive. (C) 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Autoimmunity Reviews

ISSN

1568-9972

e-ISSN

—

Volume of the periodical

16

Issue of the periodical within the volume

6

Country of publishing house

US - UNITED STATES

Number of pages

8

Pages from-to

658-665

UT code for WoS article

000400969200012

EID of the result in the Scopus database

2-s2.0-85018924549